Gottlieb Initiative Will Expedite Device, Drug Pain Control Alternatives, FDA Chief Says

US FDA Chief Scott Gottlieb said he will soon announce an initiative to help expedite approvals of both innovative devices and drugs that are designed to control pain as an alternative to opioid prescriptions commonly written by doctors.

An ampoule Opioid next to it is a note written in English Opioid epidemic. All around, many tablets and syringes are scattered.

Sponsors of new pain-control devices should get a boost from what FDA Commissioner Scott Gottlieb said will be “a new initiative for companies that have products to treat pain,” during a May 3 talk at the Medical Device Manufacturers Association meeting in Washington, D.C.

“We want to put on the market alternatives for pain control that aren’t addictive," he told attendees. There is an...

Medtech Insight Podcast

Keep up with the top medtech business and regulatory news.

Medtech Insight brings you interviews and analysis, on the go.

More from United States

Global Medtech Guidance Tracker: September 2024

 
• By 

Stay current on regulatory guidelines from around the world with Medtech Insight's Guidance Tracker. Over 40 documents have been posted on the tracker since its last update.

Senseonics Readies For US Launch Of 'World’s First One-Year CGM'

 

US FDA has greenlighted Senseonics’ Eversense 365 continuous glucose monitor, which must be replaced just once a year. Capable of being integrated with compatible insulin pumps as part of an automated insulin delivery system, the fully implantable device lasts 185 days longer than the Eversense E3 sensor and far outstrips competing CGMs, which last only for 10-14 days.

Does SCOTUS Chevron Decision Tip The Scales In Favor Of Industry?

 

With the reversal of the Chevron doctrine in June, lower courts will now have more say in deciding regulatory statutes when the language is murky. But will that open the door to more legal challenges from the healthcare industry against government regulations it finds unfavorable? A pair of legal experts recently discussed the potential implications of the Court’s decision.

FDA Releases Six More De Novo Summaries

 
• By 

The US FDA released six more device classifications in early September, including products from Edwards, Interscope, and Baxter Healthcare.

More from North America

News We’re Watching: $1B Judgement Against J&J Recalls For Abbott, Baxter, More; Karl Storz Announces Fujifilm Partnership

 

This week, a Delaware court awarded Auris Health shareholders $1bn in a lawsuit against Johnson & Johnson; Abbott recalled some FreeStyle Libre 3 sensors; and McKesson purchased a controlling interest in a Florida cancer care chain.

Global Medtech Guidance Tracker: August 2024

 
• By 

Stay current on regulatory guidelines from around the world with Medtech Insight's Guidance Tracker. Nearly 80 documents have been posted on the tracker since its last update.

Final Guidance Sets Date For Mandatory De Novo Electronic Submissions

 

The Food and Drug Administration’s final guidance outlines the agency’s thinking for sponsors submitting de novo requests electronically, which they must starting in October 2025.